Natco Pharma Ltd’s consolidated net profit declined 22.5 per cent to ₹93 crore in the fourth quarter ended March 31, against ₹120 crore profit recorded in the corresponding quarter last year.
The total revenue of the Hyderabad-based company was marginally down at ₹477 crore (₹487 crore).
For the full year ended March 31, the drug maker posted 9 per cent decline in revenue at ₹2,022 crore against ₹2,225 crore in previous fiscal. The net profit for the period declined 29 per cent to ₹458 crore (₹642 crore).
“The overall decline in revenue and profits, from the prior year, was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures,’’ the company said in a release.
The company also faced slowdown in business operations during the fourth quarter due to supply chain issues amidst Covid-19 concerns, which were subsequently resolved, it added.
The board of directors recommended a fourth interim dividend of ₹1.00 per equity share of ₹2 each, resulting in a total dividend payout of ₹6.75 per equity share for the year.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.